Artificial Intelligence (AI) is a rapidly growing and evolving field impacting pharmacy research, education, and professional practice. The development and adaptation of AI technologies have the potential to radically shape the future of the pharmacy profession. However, it remains unclear how aware pharmacists are of these technologies or their perceptions regarding current and future utilization. The purpose of this study is to describe the perceptions and awareness of artificial intelligence technologies in a population of practicing pharmacists across the US. A 19-question electronic survey was administered via Qualtrics™ to assess various AI perceptions among U.S. pharmacists. The survey ran from September 5th to November 22nd, 2023 and targeted practicing pharmacists through professional organizations and publicly available email lists. Responses were analyzed for descriptive trends and demographic analysis focusing on factors predicting AI use and were categorized into sub-focuses for detailed analysis. A total of 1363 practicing pharmacists completed the survey. 82.5% of respondents expressed some degree of familiarity with AI software, but only 38.7% reported having used AI. Of those using AI software, the most common applications were Large Language Models (33.7%) and Image Generation (10%). 56.1% of pharmacists feel that AI will decrease the number of pharmacy jobs, and 34.9% of pharmacists express some degree of distrust of AI. Despite this, 64.1% of pharmacists feel that AI could enhance their professional effectiveness and productivity. Males appear much more likely than females to use AI (50.1% vs 31%, p<.001). Younger responders also reported higher AI utilization with the highest utilization aged 23-29 (47.5%) and lowest in 60+ (25.6%, p<.001) CONCLUSION: Understanding pharmacists' current awareness, concerns, and perspectives on AI is crucial for navigating its potential impact on the profession including potential professional utilization, addressing concerns regarding job security, ethical considerations, and regulatory uncertainty.
Objective: Traumatic brain injury (TBI) is a major cause of death and disability worldwide. Many patients who experience severe TBI have persistent disorders of consciousness. Amantadine and modafinil are used for some neurological disorders; however, a comparison of the 2 medications in TBI has not been reported. This study compared the effectiveness of amantadine, modafinil, and standard of care (SOC) on disorders of consciousness after TBI. Methods: All adult TBI patients admitted between January 1, 2017, and September 31, 2020 who received amantadine, modafinil, or SOC treatments were screened. Data collection included: demographics, change in Glasgow Coma Scale (GCS), location of hemorrhage, medication duration, intensive care unit and hospital length of stay, adverse drug reactions, and concomitant sedative medications. Patients in the amantadine and modafinil groups were matched 1:2 with patients who received SOC therapies. The primary outcome was change in GCS ≥ 3 from baseline to discharge. Results: A total of 142 patients met inclusion criteria. Medications were initiated a median of 8 days from admission. Patients in the SOC group experienced a greater improvement in GCS and shorter hospital length of stay compared with amantadine. A change in GCS ≥ 3 from medication initiation to hospital discharge occurred in 46.5% of amantadine patients and 53.8% of modafinil patients. Conclusions: In this study, TBI patients did not benefit from amantadine or modafinil compared with SOC therapies, and no differences were found between medication groups. Further studies are warranted to determine whether the addition of amantadine or modafinil in the weeks after TBI provides benefit.
1 January 2021 in The Journal of Pediatric Pharmacology and Therapeutics
Toxic epidermal necrolysis is a rare, life-threatening skin disease with no consensus on adjunctive treatment, particularly in pediatric patients. We present the case of a 13-year-old previously healthy patient with drug-associated toxic epidermal necrolysis who experienced significantly shortened length of hospital stay and duration of symptoms compared with published literature when treated with 2 doses of etanercept 50 mg during 5 days.
2 January 2023 in Pulmonary Pharmacology & Therapeutics
Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in the emergency department (ED) and when patients present in acute AF with rapid ventricular rate (RVR), it can result in significant morbidity and mortality. Primary treatment modalities are aimed at rate control with the two most common agents being intravenous metoprolol and diltiazem. Some evidence suggests that diltiazem may be more effective at controlling rate in these patients; however, the dosing strategies, pharmacologic differences, and study designs may play a role in the observation of these differences. The purpose of this article is to review the evidence for using weight-based metoprolol in the treatment of AF with RVR. The vast majority of studies comparing metoprolol and diltiazem for the treatment of acute AF with RVR compare a flat dose of metoprolol to a weight-based dose of diltiazem. Following a comprehensive review, only two studies have compared a weight-based dosing strategy of intravenous (IV) metoprolol versus IV diltiazem for this disease state. Overall, the two studies only contained 94 patients and failed to meet power. Beyond differing dosing strategies, differences in pharmacokinetics between the two medications (like the onset of action and metabolism) could have played a role in the differences observed in the studies. Further studies are warranted to provide better guidance on which agent should be used in the treatment of acute AF with RVR.